Jun 2026 (Q2 FY26) — Aug 4, 2026
Astera Labs Q2 FY26 — Record Revenue and Scorpio X-Series Volume Production
Read the full callAstera Labs (ALAB) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Astera Labs earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 392 | +104.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 22.7 | +2.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 153 | +198.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
45 of 52 judged targets kept · 32 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Interest Income | approximately $11 million | Mar 2026 | For the second quarter, interest and other income was $12.1 million. | Achieved |
| Non-GAAP Operating Expenses | between $128 million and $131 million | Mar 2026 | Non-GAAP operating expenses for the second quarter were $135.8 million, up 10% sequentially, reflecting continued investment in our road map. | Missed |
| Scorpio product line revenue contribution | become our largest product line | Mar 2026 | We expect Scorpio to become our largest product family in Q3, which is 1 quarter ahead of our prior expectations, marking an important strategic milestone. | Revised Up |
7 of Astera Labs, Inc.'s 84 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 81 more targets are in the full ledger.
Claimed
- Achieved record revenue of $392.4 million, representing a 27% sequential increase and 104% year-over-year growth.
- PCIe 6 products accounted for over 50% of total revenue in Q2, a significant increase from 1/3 in Q1, demonstrating market leadership.
- Scorpio X-Series entered volume production and is projected to become the largest product family by revenue in Q3, one quarter ahead of prior expectations.
- Reported non-GAAP diluted EPS of $0.80, an increase of over 30% from Q1.
- Expanded non-GAAP operating margin to 39.1%, up 290 basis points sequentially, driven by strong revenue growth and operating leverage.
Qualified
- While absolute revenues from China are expected to increase, they will likely remain in the single digits as a percentage of total revenue due to faster growth in other regions.
Price
$286.58 +0.27% · +$0.76
Performance +79.3% 1Y
1Y: $159.8 on 17 Oct 2025 → $286.58. High $483.02 (30 Jun 2026), low $100.27 (30 Mar 2026).
- Previous close
- $285.82
- 52-week range
- $100.27 – $483.02
- One year
- +83.34%
Overview
- Symbol
- ALAB
- Sector
- Information Technology
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
45 of 52 judged targets kept · 32 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Interest Income | approximately $11 million | Mar 2026 | For the second quarter, interest and other income was $12.1 million. | Achieved |
| Non-GAAP Operating Expenses | between $128 million and $131 million | Mar 2026 | Non-GAAP operating expenses for the second quarter were $135.8 million, up 10% sequentially, reflecting continued investment in our road map. | Missed |
| Scorpio product line revenue contribution | become our largest product line | Mar 2026 | We expect Scorpio to become our largest product family in Q3, which is 1 quarter ahead of our prior expectations, marking an important strategic milestone. | Revised Up |
Claimed
- Achieved record revenue of $392.4 million, representing a 27% sequential increase and 104% year-over-year growth.
- PCIe 6 products accounted for over 50% of total revenue in Q2, a significant increase from 1/3 in Q1, demonstrating market leadership.
- Scorpio X-Series entered volume production and is projected to become the largest product family by revenue in Q3, one quarter ahead of prior expectations.
- Reported non-GAAP diluted EPS of $0.80, an increase of over 30% from Q1.
- Expanded non-GAAP operating margin to 39.1%, up 290 basis points sequentially, driven by strong revenue growth and operating leverage.
Qualified
- While absolute revenues from China are expected to increase, they will likely remain in the single digits as a percentage of total revenue due to faster growth in other regions.
The full ledger
Open Astera Labs, Inc.’s full ledger
A free account opens 5 company ledgers a month. All 84 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 5, 2026
Astera Labs Q1 FY26 — Revenue up 93% YoY on broad-based AI fabric and signal conditioning strength
Read the full callDec 2025 (Q4 FY25) — Feb 10, 2026
Astera Labs Q4 FY25 — Strong Revenue Growth and Strategic Investments in AI Connectivity
Read the full callEvery analysed call
Astera Labs earnings calls (ALAB)
Financials
What the filings say
Net profit, year on year: +199% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 113 | 141 | 159 | 192 | 231 | 271 | 308 | 392 |
| Operating profit | -9 | 0 | 11 | 40 | 55 | 67 | 62 | 89 |
| Operating margin | −7.9% | 0.1% | 7.1% | 20.7% | 24.0% | 24.8% | 20.1% | 22.7% |
| Profit before tax | 2 | 11 | 22 | 51 | 67 | 79 | 73 | 103 |
| Tax rate | 476.6% | −130.9% | −46.5% | −1.1% | −36.3% | 43.0% | −9.4% | −48.9% |
| Net profit | -8 | 25 | 32 | 51 | 91 | 45 | 80 | 153 |
| EPS ($ per share) | -0.05 | — | 0.19 | 0.31 | 0.54 | — | 0.47 | 0.89 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 |
| Reserves | — | -125 | -209 | 10 |
| Total liabilities | — | 39 | 90 | 168 |
| Fixed assets | — | 5 | 36 | 92 |
| Total assets | — | 196 | 1,055 | 1,532 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Cash from operations | -36 | -13 | 137 | 319 |
| Cash from investing | -91 | -18 | -758 | -241 |
| Cash from financing | 152 | -1 | 656 | 10 |
| Net cash flow | 25 | -31 | 35 | 88 |
| Capital expenditure | -4 | -3 | -34 | -38 |
| Free cash flow | -40 | -15 | 102 | 282 |
ALAB revenue by segment
| Segment | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|
| Reportable | 100% | 100% | 100% | 100% | 100% | 100% | +104.5% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- CN 39% ↑ 24 pt
- SG 29% ↑ 18 pt
- TW 27% ↓ 41 pt
- Non Us 4% ↑ 2 pt
- US 1% ↓ 3 pt
As ALAB cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
529 filings between Nov 14, 2025 and Oct 7, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$784.07M
504 sales by 8 insiders
71% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 19
- Award — granted as compensation
Also filed: 6 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Gajendra Sanjay | — | $318.61M | Aug 17, 2026 |
| Mohan Jitendra | — | $234.10M | Aug 17, 2026 |
| ALBA MANUEL | — | $182.60M | Sep 1, 2026 |
| Dyckerhoff Stefan A | — | $29.09M | Oct 7, 2026 |
| Mazzara Philip | — | $11.12M | Aug 17, 2026 |
| LAZAR JACK R | — | $5.15M | Jun 4, 2026 |
| Tate Michael Truett | — | $3.14M | Feb 17, 2026 |
| Mayer Bethany | — | $271.0K | Jun 24, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 7, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 8,333 | $3.13M |
| Oct 7, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 3,505 | $1.32M |
| Oct 7, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 661 | $248.6K |
| Oct 1, 2026 | Dyckerhoff Stefan A Director | Award 10b5-1 plan | 68 | $21.2K |
| Oct 1, 2026 | HURLSTON MICHAEL E. Director | Award | 72 | $22.4K |
| Oct 1, 2026 | BARRATT CRAIG H Director | Award | 68 | $21.2K |
| Sep 2, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 2,275 | $625.1K |
| Sep 2, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 1,867 | $514.4K |
| Sep 2, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 172 | $47.6K |
| Sep 2, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 52 | $14.2K |
| Sep 2, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 32 | $8.9K |
| Sep 2, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 148 | $40.8K |
| Sep 2, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 407 | $112.6K |
| Sep 2, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 273 | $74.7K |
| Sep 2, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 650 | $177.9K |
| Sep 2, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 5,409 | $1.49M |
| Sep 2, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 429 | $117.9K |
| Sep 2, 2026 | Dyckerhoff Stefan A Director | Sale 10b5-1 plan | 785 | $216.3K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 225 | $64.8K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 588 | $168.8K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 196 | $56.6K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 491 | $139.5K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 8,179 | $2.28M |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 2,835 | $797.1K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 74 | $21.1K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 892 | $257.7K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 340 | $97.0K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 568 | $157.5K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 12,882 | $3.62M |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 20,991 | $5.84M |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 2,575 | $714.1K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 37,176 | $10.38M |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 59,379 | $16.63M |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 5,870 | $1.66M |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 3,954 | $1.12M |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 2,245 | $638.0K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 2,677 | $768.3K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 1,019 | $293.4K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 4,618 | $1.29M |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 13,070 | $3.66M |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 1,288 | $363.4K |
| Sep 1, 2026 | ALBA MANUEL Director | Sale 10b5-1 plan | 868 | $245.8K |
| Aug 17, 2026 | Mazzara Philip General Counsel and Secretary | Sale | 610 | $206.5K |
| Aug 17, 2026 | Mazzara Philip General Counsel and Secretary | Sale | 504 | $171.2K |
| Aug 17, 2026 | Mohan Jitendra Chief Executive Officer | Sale | 2,946 | $991.8K |
| Aug 17, 2026 | Mazzara Philip General Counsel and Secretary | Sale | 205 | $69.8K |
| Aug 17, 2026 | Mazzara Philip General Counsel and Secretary | Sale | 125 | $42.7K |
| Aug 17, 2026 | Mohan Jitendra Chief Executive Officer | Sale | 10,438 | $3.53M |
| Aug 17, 2026 | Mohan Jitendra Chief Executive Officer | Sale | 17,373 | $5.99M |
| Aug 17, 2026 | Mazzara Philip General Counsel and Secretary | Sale | 415 | $142.3K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Astera Labs, Inc.
Free account. Everything above stays public.
Write why you follow Astera Labs, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading